Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
12 août 2024 16h10 HE
|
OncoCyte Corporation
Oncocyte’s VitaGraft™ Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study
Oncocyte Announces Successful GraftAssure™ Beta Launch and Q2 2024 Results
08 août 2024 16h05 HE
|
OncoCyte Corporation
Oncocyte Announces Successful GraftAssureTM Beta Launch and Q2 2024 Results
Oncocyte Announces August Investor Conferences Participation
05 août 2024 16h05 HE
|
OncoCyte Corporation
Oncocyte Announces August Investor Conferences Participation
Oncocyte to Announce Second Quarter 2024 Financial Results on August 8
01 août 2024 16h05 HE
|
OncoCyte Corporation
Oncocyte to Announce Second Quarter 2024 Financial Results on August 8
Oncocyte Appoints Andrea James as Chief Financial Officer
17 juin 2024 16h05 HE
|
OncoCyte Corporation
Oncocyte Appoints Seasoned Finance Executive Andrea James as Chief Financial Officer
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
30 mai 2024 16h47 HE
|
OncoCyte Corporation
Late-breaking presentation of data at American Transplant Congress on Monday, June 3Data show potential to monitor for therapeutic efficacy and recurrencePotential repeat testing opportunities with...
Oncocyte Reports First Quarter 2024 Financial Results
15 mai 2024 16h05 HE
|
OncoCyte Corporation
ONCOCYTE REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Oncocyte to Announce First Quarter 2024 Financial Results
13 mai 2024 08h00 HE
|
OncoCyte Corporation
Oncocyte to Announce First Quarter 2024 Financial Results
Oncocyte Reports Full Year 2023 Financial Results
12 avr. 2024 06h00 HE
|
OncoCyte Corporation
ONCOCYTE REPORTS FULL YEAR 2023 FINANCIAL RESULTS
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
11 avr. 2024 21h46 HE
|
OncoCyte Corporation
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules